摘要:
The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.
摘要:
The invention provides cytotoxic T lymphocytes that express a chimeric cell surface receptor. The chimeric receptor enables the lymphocytes to become activated and to proliferate (via a T.sub.H -independent autocrine cycle) in response to adhesion between the lymphocyte and an antigen displaying cell (ADC) that might not normally activate the T cell. The chimeric receptors of the present invention comprise fusion polypeptides of the following structure:XC--TM--IC28wherein (XC) is an extracellular region derived from a receptor for a ligand that is expressed on the surface of an antigen-displaying cell, fused via a transmembrane region is (TM) to an intracellular region (IC28) which is derived from the intracellular region of the CD28 receptor.
摘要:
The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.